Learning Objectives
- Demonstrate an increase in your knowledge of clinical medicine.
- Evaluate the appropriateness of clinical information as it applies to the care of your patients.
- Demonstrate an improvement in your ability to make decisions that provide safe and effective medical care.
- Recognize areas of personal strength and areas for growth in clinical knowledge.
Intended Audience
Physicians, residents, and physician assistants who are seeking to maintain and augment their knowledge in family medicine and/or who are preparing for their initial board certification or recertification.
Accreditation
The Massachusetts Medical Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
AMA Credit Designation Statement
The Massachusetts Medical Society designates this enduring material for a maximum of 349 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
AAFP Prescribed Credit
The AAFP has reviewed NEJM Knowledge+ Family Medicine Board Review and deemed it acceptable for up to 349.00 Enduring Materials, Self-Study AAFP Prescribed credits. Term of Approval is from 02/01/2024 to 01/31/2025. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA Self-Assessment CME Credit
This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 20 AAPA Category 1 Self-Assessment CME credits. PAs should only claim credit commensurate with the extent of their participation. Approval is valid from 5/1/2023 to 4/30/2024. AAPA reference number: CME-209251.
For NCCPA certification maintenance ONLY: NCCPA will now apply an additional 50 percent weighting when these self-assessment credits are logged for NCCPA certification maintenance purposes. PAs should log up to a maximum of 20 AAPA Category 1 Self-Assessment CME credits, as the additional weighting will be automatically applied by NCCPA.
Method of Participation
You must answer questions correctly to receive AMA PRA Category 1 Credits™, AAFP Prescribed credits, and AAPA Category 1 Self-Assessment CME credits toward Certification Maintenance.
Six questions answered correctly are designated for 1 AMA PRA Category 1 Credit™, 1 AAFP Prescribed credit, and 1 AAPA Category 1 Self-Assessment CME credit.
CME Accreditation Term
Original Release Date: February 1, 2015
Review dates: 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024
Termination Date: February 1, 2025
MMS Disclosure Policy
The Massachusetts Medical Society (MMS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) and must ensure independence, balance, and scientific rigor in its accredited continuing education activities.
All individuals in control of the content for an MMS accredited continuing education activity must disclose all financial relationships with ineligible companies for the previous 24 months.
Individual Disclosures
Below are all relevant financial relationships reported by NEJM Knowledge+ contributors during the past 3 years.
Vaneeta Bamba, MD| 2022 | Nothing disclosed |
| 2023 | Nothing disclosed |
| 2024 | Novo Nordisk, Scientific Advisory Board on Long-Acting Growth Hormone, discontinued Oct 2023 |
| 2022 | Rune Labs, consultant |
| 2023 | Nothing disclosed |
| 2022 | Pfizer, advisory board member, discontinued May 2021 Novartis, advisory board member, discontinued Dec 2021 |
| 2024 | Pfizer, advisory board member, discontinued Mar 2023 Scholar Rock, consultant, discontinued Sep 2022 Argenx, advisory board member, discontinued Nov 2022 |
| 2022 | Nothing disclosed |
| 2023 | Presidio, scientific board member |
| 2024 | Nothing disclosed |
| 2022 | Takeda Pharmaceutical, consultant |
| 2023 | Takeda Pharmaceutical, consultant Octapharma, honoraria Genentech, advisory board member Doximity, equity |
| 2024 | Takeda Pharmaceutical, consultant and advisory board member Octapharma, honoraria Sanofi, advisory board member Pfizer, honoraria Bayer, advisory board member Doximity, equity |
| 2022 | Actuate Therapeutics, grant/funding Bicara, consultant/advisory board Bicara, grant/funding Boxer Capital, consultant Bristol Myers Squibb, grant/funding Bristol Myers Squibb, consultant Coherus, consultant Elevar, consultant/advisory board Exicure, grant/funding, discontinued Jan 2022 Exicure, consultant/advisory board Gateway for Cancer Research, grant/funding Genentech, grant/funding General Catalyst, consultant GlaxoSmithKline, grant/funding ImmunityBio, grant/funding Kartos Therapeutics, grant/funding Kite Pharma, grant/funding, discontinued Jun 2022 KSQ Therapeutics, consultant KSQ Therapeutics, grant/funding Kura Oncology, consultant/advisory board Kura Oncology, grant/funding Merck, consultant/advisory board Naveris, consultant/advisory board Prelude, consultant/advisory board Rain Therapeutics, consultant, discontinued Nov 2021 Regeneron, consultant/advisory board Regeneron, grant/funding Remix Therapeutics, consultant/advisory board Repertoire, grant/funding Sanofi Genzyme, advisory board, discontinued Nov 2021 Sanofi Genzyme, grant/funding Secura Bio, grant/funding V Foundation, grant/funding, discontinued Jun 2022 |
| 2024 | ACCRF, grant/funding Actuate Therapeutics, grant/funding ASCO Conquer Cancer Foundation, grant/funding Bicara, grant/funding Bicara, consulting/advisory boards and honoraria Bristol-Myers Squibb, grant/funding Boxer Capital, consulting/advisory boards and honoraria, discontinued Jun 2023 Coherus, consulting/advisory boards and honoraria Elevar, grant/funding Elevar, consulting/advisory boards and honoraria, discontinued Nov 2022 Exicure, grant/funding Gateway for Cancer Research, grant/funding Genentech, grant/funding GlaxoSmithKline, grant/funding Grey Wolf Therapeutics, consulting/advisory boards and honoraria, discontinued Feb 2024 Guardian Bio, consulting/advisory boards and honoraria, discontinued Apr 2023 ImmunityBio, grant/funding Inhibrx, consulting/advisory boards and honoraria Kartos Therapeutics, grant/funding Kite Pharma, grant/funding KSQ Therapeutics, grant/funding KSQ Therapeutics, consulting/advisory boards and honoraria, discontinued Nov 2022 Kura Oncology, grant/funding Kura Oncology, consulting/advisory boards and honoraria Merck, consulting/advisory boards and honoraria Naveris, consulting/advisory boards and honoraria Nextech, consulting/advisory boards and honoraria, discontinued May 2023 PDS Biotech, consulting/advisory boards and honoraria, discontinued Oct 2023 Regeneron, grant/funding Regeneron, consulting/advisory boards and honoraria Remix, consulting/advisory boards and honoraria, discontinued Apr 2023 Repertoire, grant/funding Replimune, consulting/advisory boards and honoraria Sanofi Genzyme, grant/funding Secura Bio, grant/funding Surface Oncology, consulting/advisory boards and honoraria, discontinued May 2023 V Foundation, grant/funding |
| 2022 | Pfizer, consultant, discontinued Dec 2020 Biogen, consultant, discontinued Dec 2020 Novartis, consultant |
| 2023 | Fresenius Kabi, consultant Novartis, consultant |
| 2024 | Novartis, consultant |
| 2022 | Analysis Group, research support to institution, discontinued Nov 2020 Celgene (Bristol Myers Squibb), research support to institution, discontinued Nov 2020 Novartis, research support |
| 2023 | Novartis, research support |
| 2024 | Novartis, research support |
| 2022 | PI for Kaneka study and Visterra study |
| 2022 | Nothing disclosed |
| 2023 | Elevate, cofounder and chief medical officer Fern Health, medical advisor |
| 2022 | Boston Scientific, consultant |
| 2023 | Boston Scientific, consultant |
| 2024 | Boston Scientific, consultant Olympus, consultant |
| 2023 | Epigenyx Therapeutics, consultant UCB, principal investigator for a clinical trial Eisai, principal investigator for a clinical trial |
| 2024 | Epigenyx Therapeutics, consultant |
| 2022 | Janssen, advisory committee |
| 2023 | Janssen, consultant |
| 2024 | Nothing disclosed |
| 2023 | Napo Pharmaceuticals, scientific advisory board Actimed Therapeutics, scientific advisory board Meter Health, scientific advisory board Veloxis Pharmaceuticals, consultant Aileron Therapeutics, consultant BYOMass, consultant Takeda, advisory board Enzychem Lifesciences Pharmaceutical Company, data safety monitoring board |
| 2024 | Actimed Therapeutics, scientific advisory board Takeda, scientific advisory board, discontinued Apr 2022 Napo Pharmaceuticals, scientific advisory board Meter Health, scientific advisory board, discontinued May 2022 Pfizer, speaker, discontinued Sep 2023 Dexcel Pharma, consultant, discontinued Sep 2023 |
| 2022 | Nothing disclosed |
| 2023 | Horizon, consultant Alexion, consultant |
| 2024 | Nothing disclosed |
| 2022 | Nothing disclosed |
| 2023 | Nothing disclosed |
| 2024 | Amgen, speakers bureau and advisory board member, discontinued Mar 2024 |
| 2023 | Indivior, research support, discontinued Aug 2023 |
| 2022 | Biomarin, ad hoc advisory board, discontinued Oct 2021 Orphazyme, ad hoc FDA advisory meeting, discontinued Oct 2021 Sio Gene Therapies, consultant, discontinued Nov 2021 Sio Gene Therapies, ad hoc advisory board, discontinued Aug 2021 Inventiva Pharmaceutical, ad hoc advisory board, discontinued Jul 2021 Takeda Pharmaceutical, ad hoc advisory board, discontinued Mar 2021 Ultragenyx, speaker, discontinued Nov 2020 Neurogene, ad hoc advisory board, discontinued Oct 2020 Regenxbio, ad hoc advisory board, discontinued Apr 2020 |
| 2023 | RegenxBio, consultant Takeda Pharmaceutical, advisory committee, discontinued 2022 Denali, drug safety monitoring board |
| 2024 | Takeda Pharmaceutical, advisory committee, discontinued Feb 2023 REGENXBIO, speaker, discontinued Feb 2023 M6P Therapeutics, advisory board member |
| 2022 | Nothing disclosed |
| 2023 | Nothing disclosed |
| 2024 | Nothing disclosed |
All relevant financial relationships have been mitigated prior to the beginning of this activity in accordance with ACCME and MMS policies. All other individuals in control of the content have reported no relevant financial relationships with ineligible companies for this activity. The complete list of contributors can be found here.
Disclosure of Commercial Support
No commercial support was received for this activity.
Medium or Combination of Media Used
This is an adaptive self-assessment tool designed to adjust to the learner’s strengths and areas for growth, and can be accessed from a desktop, laptop, tablet, or smartphone. Learners choose the subspecialty area and are presented with a sequence of questions. After each question is answered, the user is provided with the key learning point, detailed feedback that discusses the correct answer as well as each of the wrong answers, and citations to relevant articles.
Estimated Time to Complete the Educational Activity
One hour for every 6 questions answered correctly.
Bibliography
Each clinical vignette includes citations and references.
Contact Information
For all questions and comments, please contact NEJM Knowledge+ by email at knowledgeplussupport@nejm.org or call toll-free +1-855-318-9303 (within the USA and Canada) or +1-781-434-7998.
Policy on Privacy and Confidentiality
Read our Privacy Policy.
Copyright
Copyright information can be found in the NEJM Group Terms of Use.